Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 79
Filter
Add more filters

Publication year range
1.
RNA ; 19(2): 219-29, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23264568

ABSTRACT

The primer for initiating reverse transcription in human immunodeficiency virus type 1 (HIV-1) is tRNA(Lys3). Host cell tRNA(Lys) is selectively packaged into HIV-1 through a specific interaction between the major tRNA(Lys)-binding protein, human lysyl-tRNA synthetase (hLysRS), and the viral proteins Gag and GagPol. Annealing of the tRNA primer onto the complementary primer-binding site (PBS) in viral RNA is mediated by the nucleocapsid domain of Gag. The mechanism by which tRNA(Lys3) is targeted to the PBS and released from hLysRS prior to annealing is unknown. Here, we show that hLysRS specifically binds to a tRNA anti-codon-like element (TLE) in the HIV-1 genome, which mimics the anti-codon loop of tRNA(Lys) and is located proximal to the PBS. Mutation of the U-rich sequence within the TLE attenuates binding of hLysRS in vitro and reduces the amount of annealed tRNA(Lys3) in virions. Thus, LysRS binds specifically to the TLE, which is part of a larger LysRS binding domain in the viral RNA that includes elements of the Psi packaging signal. Our results suggest that HIV-1 uses molecular mimicry of the anti-codon of tRNA(Lys) to increase the efficiency of tRNA(Lys3) annealing to viral RNA.


Subject(s)
Genome, Viral/genetics , HIV-1/genetics , Lysine-tRNA Ligase/genetics , RNA, Transfer, Lys/genetics , RNA, Viral/genetics , gag Gene Products, Human Immunodeficiency Virus/metabolism , Base Pairing , Electrophoretic Mobility Shift Assay , HIV Enhancer/genetics , HIV-1/physiology , Humans , Lysine-tRNA Ligase/metabolism , Molecular Mimicry , Mutation , Protein Structure, Tertiary , RNA , RNA, Transfer, Lys/chemistry , RNA, Transfer, Lys/metabolism , RNA, Viral/metabolism , Virus Assembly/genetics , Virus Replication/genetics
2.
J Virol ; 82(7): 3632-41, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18216101

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1) gene expression is controlled by a complex interplay between viral and host factors. We have previously shown that interferon-regulatory factor 1 (IRF-1) is stimulated early after HIV-1 infection and regulates promoter transcriptional activity even in the absence of the viral transactivator Tat. In this work we demonstrate that IRF-1 is also required for full NF-kappaB transcriptional activity. We provide evidence that IRF-1 and NF-kappaB form a functional complex at the long terminal repeat (LTR) kappaB sites, which is abolished by specific mutations in the two adjacent kappaB sites in the enhancer region. Silencing IRF-1 with small interfering RNA resulted in impaired NF-kappaB-mediated transcriptional activity and in repressed HIV-1 transcription early in de novo-infected T cells. These data indicate that in early phases of HIV-1 infection or during virus reactivation from latency, when the viral transactivator is absent or present at very low levels, IRF-1 is an additional component of the p50/p65 heterodimer binding the LTR enhancer, absolutely required for efficient HIV-1 replication.


Subject(s)
HIV Enhancer/genetics , HIV Long Terminal Repeat/genetics , HIV-1/physiology , Interferon Regulatory Factor-1/metabolism , NF-kappa B/metabolism , Binding Sites , Cell Line , Electrophoretic Mobility Shift Assay , Gene Silencing , HIV-1/genetics , Humans , Immunoprecipitation , Interferon Regulatory Factor-1/antagonists & inhibitors , Point Mutation , Protein Binding , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocytes/virology
3.
Science ; 250(4983): 997-1000, 1990 Nov 16.
Article in English | MEDLINE | ID: mdl-2237444

ABSTRACT

Alteration of gene transcription by inhibition of specific transcriptional regulatory proteins is necessary for determining how these factors participate in cellular differentiation. The functions of these proteins can be antagonized by several methods, each with specific limitations. Inhibition of sequence-specific DNA-binding proteins was achieved with double-stranded (ds) phosphorothioate oligonucleotides that contained octamer or kappa B consensus sequences. The phosphorothioate oligonucleotides specifically bound either octamer transcription factor or nuclear factor (NF)-kappa B. The modified oligonucleotides accumulated in cells more effectively than standard ds oligonucleotides and modulated gene expression in a specific manner. Octamer-dependent activation of a reporter plasmid or NF-kappa B-dependent activation of the human immunodeficiency virus (HIV) enhancer was inhibited when the appropriate phosphorothioate oligonucleotide was added to a transiently transfected B cell line. Addition of phosphorothioate oligonucleotides that contained the octamer consensus to Jurkat T leukemia cells inhibited interleukin-2 (IL-2) secretion to a degree similar to that observed with a mutated octamer site in the IL-2 enhancer. The ds phosphorothioate oligonucleotides probably compete for binding of specific transcription factors and may provide anti-viral, immunosuppressive, or other therapeutic effects.


Subject(s)
Gene Expression Regulation , Oligonucleotides/genetics , Thionucleotides/genetics , DNA-Binding Proteins/metabolism , Gene Expression Regulation, Neoplastic , Gene Expression Regulation, Viral , HIV Enhancer , Host Cell Factor C1 , Humans , Interleukin-2/antagonists & inhibitors , Leukemia, T-Cell/genetics , NF-kappa B/metabolism , Octamer Transcription Factor-1 , T-Lymphocytes , Transcription Factors/metabolism , Tumor Cells, Cultured
4.
Retrovirology ; 5: 25, 2008 Mar 07.
Article in English | MEDLINE | ID: mdl-18328091

ABSTRACT

BACKGROUND: The pathogenic significance of coreceptor switch in the viral infection of HIV-1 is not completely understood. This situation is more complex in subtype C infection where coreceptor switch is either absent or extremely rare. To gain insights into the mechanisms that underlie coreceptor requirement of subtype C, we screened several primary viral isolates and identified a clinical sample that demonstrated a potential to grow on standard T-cell lines with no detectable CCR5 expression. The subject was diagnosed with HIV-1 associated dementia in the absence of opportunistic infections of the brain. To isolate molecular clones from this virus, we devised a novel strategy based on anchor primers that target a sequence in the reverse transcriptase, highly conserved among diverse subtypes of HIV-1. RESULTS: Using this strategy, we isolated 8 full-length molecular clones from the donor. Two of the eight molecular clones, 03In94_D17 and 03In94_D24, (D17 and D24) generated replication-competent viruses. Phylogenetic analysis of the full-length viral sequences revealed that both clones were non-recombinant subtype C viruses. They contain intact open reading frames in all the viral proteins. Both the viral clones are endowed with several unique molecular and biological properties. The viral promoter of the clones is characterized by the presence of four NF-kB binding elements, a feature rarely seen in the subtype C HIV-1 LTR. Interestingly, we identified the coexistence of two different forms of Rev, a truncated form common to subtype C and a full-length form less common for this subtype, in both proviral and plasma virus compartments. An exceptional property of the viruses, atypical of subtype C, is their ability to use a wide range of coreceptors including CCR5, CXCR4, and several others tested. Sequence analysis of Env of D17 and D24 clones identified differences within the variable loops providing important clues for the expanded coreceptor use. The V1, V2 and V4 loops in both of the molecular clones are longer due to the insertion of several amino acid residues that generated potential N-linked glycosylation sites. CONCLUSION: The exceptional biological and molecular properties of these clones make them invaluable tools to understand the unique pathogenic characteristics of subtype C.


Subject(s)
AIDS Dementia Complex/virology , HIV Seropositivity/virology , HIV-1/physiology , Receptors, HIV/metabolism , Adult , Cell Line , Cloning, Molecular , Genetic Variation , HIV Enhancer/genetics , HIV Long Terminal Repeat/genetics , HIV-1/chemistry , HIV-1/classification , HIV-1/isolation & purification , Humans , Leukocytes, Mononuclear/virology , Male , Phylogeny , Proviruses/genetics , Receptors, CCR5 , Sequence Analysis , T-Lymphocytes/immunology , T-Lymphocytes/virology , env Gene Products, Human Immunodeficiency Virus/genetics , rev Gene Products, Human Immunodeficiency Virus/genetics
5.
Mol Cell Biol ; 11(4): 1883-93, 1991 Apr.
Article in English | MEDLINE | ID: mdl-2005886

ABSTRACT

In this report we introduce a simple, fast, and reliable method to prepare whole cell or nuclear extracts from small numbers of cells. These extracts were used to study transcriptional activation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) in vitro. Our results revealed that the time courses of activation of extracts derived from cells stimulated with the mitogenic lectin phytohemagglutinin (PHA) or with the tumor promoter phorbol 12-myristate 13-acetate (PMA) are different. PMA induces a rapid onset of increased in vitro transcription from the HIV-1 LTR, while PHA causes a slow and sustained response. The biochemical relevance of protein synthesis inhibition by cycloheximide treatment of cells was investigated. In these studies, PMA induction of a change in in vitro transcriptional activity is not dependent on protein synthesis. Cycloheximide alone is insufficient to induce activation. Oligonucleotide-mediated site-directed mutagenesis demonstrated that mutation of the TATA box in the LTR ablated initiation of both basal-level transcription and activation by extracts from cells stimulated with PMA. Surprisingly, mutation of both kappa B sites in the LTR reduced but did not eliminate the in vitro response to extracts prepared at early time points after PHA or PMA stimulation of Jurkat cells. The reduction was greater in extracts derived from cells treated with PMA. Deletion analysis of the HIV-1 LTR revealed at least one region (-464 to -252) capable of suppressing in vitro transcription in extracts from Jurkat cells stimulated by PMA. This result is consistent with early studies of the HIV-1 LTR in transient transfection assays. We therefore have been able to observe distinct regulatory events at early time points after cells are exposed to agents known to induce transcription of both the HIV-1 LTR reporter gene constructs and the HIV-1 provirus itself.


Subject(s)
HIV Long Terminal Repeat/genetics , HIV-1/genetics , Transcription, Genetic , Cell Line , Cycloheximide/pharmacology , HIV Enhancer , Humans , Kinetics , Mutagenesis, Site-Directed , Phytohemagglutinins/pharmacology , TATA Box , Tetradecanoylphorbol Acetate/pharmacology
6.
Mol Cell Biol ; 18(9): 5404-13, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9710624

ABSTRACT

Inefficient splicing of human immunodeficiency virus type 1 (HIV-1) RNA is necessary to preserve unspliced and singly spliced viral RNAs for transport to the cytoplasm by the Rev-dependent pathway. Signals within the HIV-1 genome that control the rate of splicing include weak 3' splice sites, exon splicing enhancers (ESE), and exon splicing silencers (ESS). We have previously shown that an ESS present within tat exon 2 (ESS2) and a suboptimal 3' splice site together act to inhibit splicing at the 3' splice site flanking tat exon 2. This occurs at an early step in spliceosome assembly. Splicing at the 3' splice site flanking tat exon 3 is regulated by a bipartite element composed of an ESE and an ESS (ESS3). Here we show that ESS3 is composed of two smaller elements (AGAUCC and UUAG) that can inhibit splicing independently. We also show that ESS3 is more active in the context of a heterologous suboptimal splice site than of an optimal 3' splice site. ESS3 inhibits splicing by blocking the formation of a functional spliceosome at an early step, since A complexes are not detected in the presence of ESS3. Competitor RNAs containing either ESS2 or ESS3 relieve inhibition of splicing of substrates containing ESS3 or ESS2. This suggests that a common cellular factor(s) may be required for the inhibition of tat mRNA splicing mediated by ESS2 and ESS3.


Subject(s)
Exons , Gene Products, tat/biosynthesis , Genes, tat , HIV-1/genetics , RNA Splicing , Regulatory Sequences, Nucleic Acid , Spliceosomes/physiology , Base Sequence , Cloning, Organism , HIV Enhancer , Humans , Kinetics , Mutagenesis, Site-Directed , RNA, Messenger/chemistry , RNA, Messenger/metabolism , RNA, Viral/chemistry , RNA, Viral/metabolism , tat Gene Products, Human Immunodeficiency Virus
7.
Mol Cell Biol ; 11(10): 4943-51, 1991 Oct.
Article in English | MEDLINE | ID: mdl-1922027

ABSTRACT

A DNA-binding factor with properties of NF-kappa B and another similar activity are rapidly induced when growth-arrested BALB/c 3T3 cells are stimulated with serum growth factors. Induction of these DNA-binding activities is not inhibited by pretreatment of quiescent cells with the protein synthesis inhibitor cycloheximide. Interestingly, the major NF-kappa B-like activity is not detected in nuclear extracts of proliferating cells, and thus its expression appears to be limited to the G0-to-G1 transition in 3T3 cells. These DNA-binding activities bind many of the expected NF-kappa B target sequences, including elements in the class I major histocompatibility complex and human immunodeficiency virus enhancers, as well as a recently identified NF-kappa B binding site upstream of the c-myc gene. Furthermore, both the class I major histocompatibility complex and c-myc NF-kappa B binding sites confer inducibility on a minimal promoter in 3T3 cells stimulated with serum growth factors. The results demonstrate that NF-kappa B-like activities are immediate-early response proteins in 3T3 cells and suggest a role for these factors in the G0-to-G1 transition.


Subject(s)
G1 Phase , Gene Expression Regulation/drug effects , Growth Substances/pharmacology , NF-kappa B/metabolism , Resting Phase, Cell Cycle , Animals , Base Sequence , Binding Sites/genetics , Cell Line , Fibroblasts , Genes, MHC Class I , Genes, myc , HIV Enhancer/genetics , Mice , Molecular Sequence Data , Promoter Regions, Genetic/genetics
8.
Mol Cell Biol ; 13(3): 1315-22, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8441377

ABSTRACT

Inducible expression of human immunodeficiency virus (HIV) is regulated by a cellular transcription factor, nuclear factor kappa B (NF-kappa B). NF-kappa B is composed of distinct subunits; five independent genes, NFKB1(p105), NFKB2(p100), RelA(p65), c-rel and relB, that encode related proteins that bind to kappa B DNA elements have been isolated. We have previously found that NFKB2(p49/p52) acts in concert with RelA(p65) to stimulate the HIV enhancer in Jurkat T-leukemia cells. Here we examine the biochemical basis for the transcriptional regulation of HIV by NFKB2. Using Scatchard analysis, we have determined the dissociation constants of homodimeric p49 and heterodimeric p49/p65 for binding to the HIV kappa B site. p49 has a approximately 18-fold-lower affinity for the HIV kappa B site (KD = 69.1 pM) than does the approximately 50-kDa protein NFKB1(p50) derived from p105 (KD = 3.9 pM). In contrast, the affinity of heterodimeric NFKB2(p49)/RelA(p65) for this site is approximately 6-fold higher (KD = 11.8 pM) than that of p49 alone. Consistent with these findings, in vitro transcription was stimulated 18-fold by the addition of preformed, heterodimeric NFKB2(p49)/RelA(p65) protein. Transcriptional activation of the HIV enhancer was also subject to regulation by recently cloned I kappa B-alpha(MAD-3). Recombinant I kappa B-alpha(MAD-3) inhibited the DNA binding activity of p65, p49/p65, and p50/p65 but stimulated the binding of NFKB2(p49) or NFKB1(p50). Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells was also inhibited by coexpression of MAD-3. These data suggest that binding of the NFKB2 subunit to the HIV enhancer is facilitated by RelA(p65) and that this NFKB2(p49)/p65 heterodimeric complex mediates transcriptional activation which is subject to regulation by MAD-3.


Subject(s)
DNA-Binding Proteins/metabolism , Gene Expression Regulation, Viral , HIV Enhancer/genetics , HIV/genetics , I-kappa B Proteins , Transcription, Genetic , Animals , B-Lymphocytes/cytology , Base Sequence , Cells, Cultured , Chloramphenicol O-Acetyltransferase/analysis , DNA Probes , DNA-Binding Proteins/pharmacology , Humans , Mice , Molecular Sequence Data , NF-KappaB Inhibitor alpha , NF-kappa B/metabolism , NF-kappa B/pharmacology , Protein Conformation , Recombinant Proteins/metabolism , Transcription Factor RelA , Transcription, Genetic/drug effects , Transfection
9.
AIDS Rev ; 8(1): 9-16, 2006.
Article in English | MEDLINE | ID: mdl-16736947

ABSTRACT

Transcriptional activation of gene expression in HIV-1 is controlled by the interaction of sequence-specific transcription factors with the long terminal repeat (LTR) of the provirus. The identification and characterization of cellular proteins involved in the process has provided a basic understanding about both general eukaryotic and HIV-1 proviral transcription regulation. The HIV-1 epidemic is expanding worldwide with an increasing number of distinct viral subtypes as well as intersubtype recombinant viruses. LTR-specific sequence variability among different HIV-1 variants could affect LTR binding to cellular and/or viral factors, influencing the extent of transcription. In vitro assays have demonstrated subtype-specific functional differences between the LTR regions of distinct HIV-1 subtypes. This observation could have consequences on the biology of the different HIV-1 clades and influence HIV-1 disease progression. Finally, the knowledge of the molecular mechanisms of transcription regulation events could help in the search for new compounds targeting the critical steps of viral transcription.


Subject(s)
Gene Expression Regulation, Viral , HIV Enhancer/physiology , HIV-1/genetics , Terminal Repeat Sequences/physiology , Anti-HIV Agents/pharmacology , Humans , Terminal Repeat Sequences/drug effects , Terminal Repeat Sequences/genetics
10.
AIDS Res Hum Retroviruses ; 21(11): 965-70, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16386115

ABSTRACT

After the identification of HIV-2 in 1986, most of the cases reported have been concentrated in West Africa. We identified a case of HIV-2 infection in São Paulo, Brazil of a 45-year-old female who presented with Pneumocystis carinii pneumonia, with a CD4 count of 22 cells/ml. DNA samples from this patient were subjected to end-point PCR amplification of the LTR region. Clones were sequenced and subjected to phylogenetic analyses. All clones were subtype A related, and four presented an insertion, corresponding to an extra NF-kappaB site. This is the first confirmed case report of an HIV-2-infected subject identified in Brazil whose transmission occurred within the country. Furthermore, the NF-kappaB duplication would potentially be associated with an increase in viral cytopathogenicity. This raises concern for the need for permanent monitoring of the spread of HIV-2 in different areas of the world, even considering its lower rate of transmission and pathogenicity when compared to HIV-1.


Subject(s)
HIV Enhancer/genetics , HIV Infections/transmission , HIV Infections/virology , HIV-2/genetics , Base Sequence , Brazil , CD4 Lymphocyte Count , Female , HIV Infections/complications , HIV Long Terminal Repeat/genetics , HIV-2/isolation & purification , Humans , Middle Aged , Molecular Sequence Data , Phylogeny , Pneumonia, Pneumocystis/complications , Sequence Analysis, DNA
11.
AIDS ; 5(3): 275-81, 1991 Mar.
Article in English | MEDLINE | ID: mdl-2059367

ABSTRACT

Three human colonic epithelial cell lines, SW620, HT29, and T84, were characterized with respect to HIV-1 infection and gene expression. SW620 and HT29, but not T84, could be infected with HIV-1. CD4 messenger RNA and its protein product were identified in SW620 cells but not in HT29 or T84 cells. Anti-CD4 antibody blocked infection of SW620 cells but had no effect on infection of HT29 cells. In SW620 and HT29 cells transfected with the HIV-1 long terminal repeat (LTR) linked to the chloramphenicol acetyl transferase (CAT) reporter gene, an intact HIV-1 enhancer element was required for stimulation of CAT activity by tumor necrosis factor alpha (TNF alpha) and phorbol ester. T84 was not able to mediate a TNF alpha or phorbol ester response. These studies provide further evidence that HIV-1 can infect cells by mechanisms other than those mediated by the CD4 receptor and describe complementary models for analyzing HIV-1 infection and expression in colonic epithelial cells.


Subject(s)
CD4 Antigens/physiology , Colon/cytology , HIV-1/physiology , CD4 Antigens/genetics , Cell Line , Epithelial Cells , Epithelium/microbiology , Gene Expression Regulation, Viral , HIV Enhancer/drug effects , HIV Long Terminal Repeat/genetics , HIV-1/genetics , Humans , Models, Biological , RNA, Messenger/analysis , Recombinant Fusion Proteins/biosynthesis , Tetradecanoylphorbol Acetate/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Virus Replication
12.
AIDS ; 5(6): 663-8, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1883541

ABSTRACT

Reactivation of latent HIV-1 is believed to play a major role in the pathogenesis of AIDS. Here we show that sodium butyrate (NaB), which can cause gene induction or cell differentiation, reactivates dormant HIV-1 in vitro in chronically infected cells of T-lymphoid and monocytoid origin. The effect of NaB on HIV-1 expression in T-lymphoid cells was apparent 3 h after addition of drug and peaked at 24 h. During this time the proportion of HIV-1 antigen expressing cells increased from less than 0.5 to greater than 90%, and virus production increased by three orders of magnitude. The virus released by the NaB-induced cells was infectious. The extent and kinetics of NaB effects were similar to effects of phorbol 12-myristate 13-acetate in T cells, but not monocytes. Transient expression assays using an indicator gene under the control of the HIV-1 long terminal repeat revealed that mutations which altered the nucleotide sequence in the TATA box significantly reduced the NaB effect. These data show that NaB is a potent inducer of dormant HIV-1 and suggest that the TATA motif is required for this activity.


Subject(s)
Butyrates/pharmacology , HIV Long Terminal Repeat/drug effects , HIV-1/drug effects , TATA Box/drug effects , Virus Activation/drug effects , Butyric Acid , Cell Line, Transformed , DNA Mutational Analysis , HIV Enhancer/drug effects , Kinetics , Monocytes/microbiology , T-Lymphocytes/microbiology , Tetradecanoylphorbol Acetate/pharmacology
13.
Gene ; 101(2): 165-70, 1991 May 30.
Article in English | MEDLINE | ID: mdl-2055485

ABSTRACT

The enhancer region of the human immunodeficiency virus (HIV) long terminal repeat (LTR) contains two 10-bp (5'-GGGACTTTCC) repeats (core enhancers) which constitute the binding sites for the ubiquitous inducible cellular transcription factor, NF-kappa B. The NF-kappa B motifs of the LTR play a central role in transcriptional activation of the LTR by several heterologous viral proteins and various external chemical and physical stimuli. Activation of the HIV enhancer by these agents may lead to the onset of HIV gene expression resulting in active viral replication. Viral genes and chemical agents, which interfere with the activity of the enhancers may be useful in inhibiting HIV gene expression, thereby suppressing HIV replication.


Subject(s)
HIV Enhancer/physiology , HIV/genetics , Transcriptional Activation/physiology , Base Sequence , Gene Expression Regulation, Viral , HIV/physiology , HIV Long Terminal Repeat/genetics , HIV Long Terminal Repeat/physiology , Molecular Sequence Data , NF-kappa B/physiology , Transcription, Genetic , Virus Replication
14.
FEBS Lett ; 509(2): 207-12, 2001 Dec 07.
Article in English | MEDLINE | ID: mdl-11741590

ABSTRACT

The effect of cAMP on the transcriptional activity of the HIV-1 long terminal repeat/enhancer was investigated and compared to the effect of cAMP on virus replication. In culture cAMP repressed virus replication in vivo using different cell types. Transient transfection studies with HIV-1 enhancer-derived luciferase reporter gene constructs identified the minimal DNA sequence mediating the negative regulatory effect of cAMP on HIV-1 transcription. A single nuclear factor kappaB element from the HIV-1 enhancer mediates the repressive effect on transcription. AP-2 is not involved in cAMP repression. Stable transfection of Jurkat T cells with the co-activators CREB binding protein (CBP) and p300 completely abolished the cAMP repressive effect, supporting the hypothesis that elevation of intracellular cAMP increases phosphorylation of CREB, which then competes with phosphorylated p65 and Ets-1 for limiting amounts of CBP/p300 thereby mediating the observed repressive effect on transcription. These findings suggest an important role of cAMP on HIV-1 transcription.


Subject(s)
Cyclic AMP/pharmacology , HIV Enhancer/drug effects , HIV-1/drug effects , Lymphocytes/virology , Virus Replication/drug effects , Binding Sites , CREB-Binding Protein , Cell Line , DNA-Binding Proteins/metabolism , HIV-1/genetics , NF-kappa B/metabolism , Nuclear Proteins/metabolism , Nucleic Acid Synthesis Inhibitors/pharmacology , Trans-Activators/metabolism , Transcription Factor AP-2 , Transcription Factors/metabolism , Transcription, Genetic/drug effects
15.
Article in English | MEDLINE | ID: mdl-1987353

ABSTRACT

The rate of transcription initiation directed by the long terminal repeat (LTR) of HIV-1 increases in response to mitogenic stimuli of T cells. Here we show that the response of the HIV-1 LTR may be governed by two independent sequences located 5' to the site of transcription initiation sequences that bind either NFAT-1 or NF kappa B. The rate of LTR-directed gene expression increased in response to treatment with either a phorbol ester or tumor necrosis factor alpha if either the NFAT-1 or NF kappa B binding sites were deleted, but failed to respond to these mitogenic stimuli if both sequences were absent. The HIV-1 mutant virus containing both NF kappa B and NFAT-1 deletion was able to replicate although at a much decreased growth rate, while the deletion of NFAT-1 alone increased the viral growth rate in Jurkat cells. Neither deletion of NF kappa B nor deletion of NFAT-1 decreased activation of viral replication by phorbol ester.


Subject(s)
HIV Long Terminal Repeat/genetics , HIV-1/genetics , Lymphocyte Activation/physiology , NF-kappa B/physiology , Transcription Factors/physiology , Cell Line , Gene Expression , HIV Enhancer/genetics , HIV-1/physiology , Humans , Lymphocyte Activation/drug effects , NF-kappa B/genetics , Plasmids , T-Lymphocytes/physiology , Tetradecanoylphorbol Acetate/pharmacology , Transcription Factors/genetics , Transfection , Tumor Necrosis Factor-alpha/pharmacology , Virus Replication
16.
Cancer Lett ; 74(1-2): 75-83, 1993 Oct 15.
Article in English | MEDLINE | ID: mdl-8287375

ABSTRACT

The regulation of trans-activating activities of two human hepatocellular carcinoma cell (HCC) lines, HEP-G2 and SK-HEP-1, was investigated. These cells were transfected with the wild-type and a nested series of its 5'-deletion mutants of the long terminal (LTR) repeat derived from HIV-1, which were ligated with the chloramphenicol acetyl transferase gene. These two HCC cell lines exhibited different biological characteristics, reflecting their status of differentiation. Both cell lines showed moderate degrees of constitutive (basal) trans-activating activities. While HEP-G2 cells, which are well differentiated, showed marked degrees of enhancement of trans-activation after treatment with 12-O-tetradecanoylphorbol-13-acetate, SK-HEP-1 cells, which are poorly differentiated, showed only moderate or low degrees of enhancement. These two cell lines up-regulated their trans-activating activities in response to the deletion of some regions of positive and negative regulatory elements, suggesting that they produce trans-acting factors that are quantitatively different from each other, and often employ different sets of positive and negative regulatory elements for trans-activation.


Subject(s)
Carcinoma, Hepatocellular/genetics , Gene Expression Regulation, Neoplastic , HIV Long Terminal Repeat/genetics , Liver Neoplasms/genetics , Regulatory Sequences, Nucleic Acid/genetics , Transcriptional Activation , Base Sequence , Carcinoma, Hepatocellular/microbiology , Cell Differentiation , Chloramphenicol O-Acetyltransferase/genetics , Chloramphenicol O-Acetyltransferase/metabolism , HIV Enhancer/genetics , HIV-1/genetics , Humans , Liver Neoplasms/microbiology , Molecular Sequence Data , NF-kappa B/metabolism , Plasmids , Promoter Regions, Genetic/genetics , Repressor Proteins/metabolism , Sp1 Transcription Factor/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Trans-Activators/metabolism , Transfection , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/microbiology , Tumor Cells, Cultured/ultrastructure , Up-Regulation
17.
AIDS Res Hum Retroviruses ; 17(9): 863-6, 2001 Jun 10.
Article in English | MEDLINE | ID: mdl-11429128

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1) proviral DNA sequences in and downstream of the 5' long terminal repeat (LTR) were compared among samples obtained from 13 HIV-1 CRF01_AE-infected individuals in Thailand from 1998 to 1999. Eleven individuals had highly conserved sequences compared with previously reported CRF01_AE viruses. However, T cell-specific factor (TCF)-1alpha motif, which is located just beside the 3' terminus of the nef sequence, was duplicated in 2 out of the 13 subjects, one of whom had also lost the 24 nucleotides next to the 3' of the primer-binding site. Thus, several characteristics of CRF01_AE LTR and gag-leader sequence were identified in some samples recently obtained in Thailand.


Subject(s)
Genetic Variation , HIV Infections/virology , HIV Long Terminal Repeat , HIV-1/genetics , Base Sequence , DNA, Viral , HIV Enhancer , HIV Infections/blood , Humans , Molecular Sequence Data , Sequence Homology, Nucleic Acid , Thailand
18.
AIDS Res Hum Retroviruses ; 8(3): 387-93, 1992 Mar.
Article in English | MEDLINE | ID: mdl-1315144

ABSTRACT

Historically, research into the regulation of gene expression in primate lentiviruses has focused on human immunodeficiency virus type 1 (HIV-1), the primary cause of acquired immunodeficiency syndrome (AIDS) in humans. The increasing emergence of HIV-2 as a human pathogen, and the importance of the various simian immunodeficiency viruses (SIV) as models for the treatment and prevention of HIV-1-induced disease, suggest that an understanding of gene regulation in these related viruses will become increasingly important. Here, the present state of knowledge in this latter field is reviewed. In general, while the data support the hypothesis that viral gene expression is regulated by very similar mechanisms in all primate lentiviruses, it also is clear that differences in detail do exist. These differences may influence the pathogenic potential of the different strains of primate lentiviruses and must be considered in evaluating SIV as an appropriate in vivo model for HIV-1.


Subject(s)
Gene Expression Regulation, Viral/physiology , Lentivirus/genetics , Amino Acid Sequence , Base Sequence , Gene Expression Regulation, Viral/genetics , Gene Products, rev/metabolism , Gene Products, tat/metabolism , HIV Enhancer/physiology , Molecular Sequence Data , NF-kappa B/metabolism , RNA, Viral/genetics , RNA, Viral/metabolism
19.
AIDS Res Hum Retroviruses ; 11(6): 761-4, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7576937

ABSTRACT

PIP: The authors determined the sequences of the LTR region of Ethiopian HIV-1 subtype C strains and compared them with Swedish HIV-1 subtype B strains and earlier published data. Peripheral blood mononuclear cells (PBMCs) were obtained from seven randomly chosen HIV-1 infected Ethiopian patients, all with pre-AIDS or AIDS. PBMCs were also obtained from three Swedish HIV-1 subtype B-infected patients. Extraction of HIV-1 DNA was performed with the phenol-chloroform plus ethanol precipitation method. In all the Ethiopian HIV-1 subtype C strains, the first five nucleotides were changed to (G/A)CAGA, a finding not observed in the Swedish subtype B strains sequenced at the same time. The most remarkable feature of the Ethiopian NF-KB region was the presence of what appears to be an extra site located upstream of the usual sites I and II. At the same time, the core enhancer sequence GGGACTTTCC at site I was modified by a deletion of the A nucleotide and a change of the first T to a G. The gross LTR organization may be radically different in "African" subtype HIV-1 isolates compared to the American/European HIV-1 subtype B prototype strains. These data from the Ethiopian strains reinforce the validity of this conclusion.^ieng


Subject(s)
Genetic Variation/genetics , HIV Enhancer/genetics , HIV-1/genetics , Amino Acid Sequence , Base Sequence , DNA, Viral/genetics , Ethiopia , Humans , Molecular Sequence Data , NF-kappa B , Phylogeny , Sequence Alignment , Sequence Analysis, DNA
20.
AIDS Res Hum Retroviruses ; 15(14): 1293-303, 1999 Sep 20.
Article in English | MEDLINE | ID: mdl-10505678

ABSTRACT

Transcription of the HIV-1 provirus genome is regulated by a complex interplay between viral regulatory proteins and cellular transcription factors that interact with the viral long terminal repeat (LTR) region of HIV-1. However, several cellular transcription factors have been identified that can interact with the HIV-1 LTR; the significance of all of these factors is not clearly understood. In this study we have characterized the LTR region of different subtypes of HIV-1 with regard to nucleotide sequence and promoter activity. The LTR regions of HIV-1 from peripheral blood mononuclear cells of 29 infected individuals originating from 10 different geographical regions were sequenced and further analyzed for promoter/enhancer activity in transient transfection of HeLa cells, in the context of a reporter gene and in the context of the complete virus genome. We found several subtype-specific LTR sequences of the various HIV-1 strains, such as an insertion that created a potential third NF-kappaB site in the LTR of the subtype C strains. The USF-binding site in the NRE also contained subtype-specific sequences. Interestingly, the promoter/enhancer activities of the subtype C LTRs were higher than the activities of the other subtypes analyzed here (subtypes A, B, D, E, and G), suggesting that the potential third NF-kappaB site may confer higher LTR activity or that the subtype C NRE may be less potent. Thus, our data suggest that genetic diversity of the LTR may result in HIV-1 subtypes with different replicative properties.


Subject(s)
HIV Enhancer/genetics , HIV Infections/genetics , HIV Long Terminal Repeat/genetics , HIV-1/genetics , Promoter Regions, Genetic/genetics , Adult , Africa/ethnology , Base Sequence , Binding Sites , Chloramphenicol O-Acetyltransferase , Enzyme-Linked Immunosorbent Assay , Female , HIV Core Protein p24/metabolism , HIV Infections/ethnology , HeLa Cells , Humans , Male , Middle Aged , Molecular Sequence Data , NF-kappa B/metabolism , Polymerase Chain Reaction , Sequence Alignment , Sweden/ethnology , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL